A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma.

Clinical trial NCT03539744 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT03539744
Sponsor: AbbVie
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Multiple Myeloma

Start date: 2018-10-22
Primary completion: 2026-08-01
Enrollment: 265

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.